{
  "openalex_id": "W4393988204",
  "doi": "https://doi.org/10.1158/1538-7445.am2024-ct136",
  "title": "Abstract CT136: Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer",
  "abstract": "Abstract Background: Pancreatic adenocarcinoma (PDAC) is an aggressive malignancy with dismal prognosis. Most patients present with advanced stages. Heightened levels of serum interleukin-6 (IL-6) are associated with carcinogenesis, immune suppression, and poor prognosis in PDAC. Preclinical data of dual inhibition of IL-6 and programmed death ligand-1 (PD-L1) facilitates CD8+ T-cell migration into pancreatic tumors and was effective in controlling tumor growth in syngeneic and genetically engineered PDAC mouse models. Siltuximab (Sil) is a chimeric monoclonal antibody which targets the IL-6 molecule specifically. Spartalizumab (Sparta) is a high-affinity ligand-blocking humanized IgG4 antibody against the PD-1 receptor. We developed a phase Ib/II trial to evaluate the safety, immunogenicity and preliminary antitumor activity of Sil and Sparta in metastatic PDAC (mPDAC). Methods: Patients (pts) with mPDAC who have progressed on at least one line of systemic chemotherapy were eligible for the trial. Other selected inclusion criteria were ≥18 years of age, ECOG PS 0-1 and measurable disease per RECIST v1.1. The phase Ib trial design is standard 3+3, with a primary endpoint of recommended phase II dose (RP2D). An additional 24 patients were planned for an expansion cohort. Sil was administered at escalating dose levels of 6 mg/kg (DL1) and 11 mg/kg (DL2), in combination with Sparta at 300 mg IV on day 1 of each 21-day cycle. Key secondary endpoints included overall response rate (ORR = CR + PR), progression-free survival (PFS) and overall survival (OS). Results: We enrolled 4 patients on DL1 and escalated to DL2/RP2D in the absence of a dose limiting toxicity (DLT). A total of 31 patients were subsequently treated at the RP2D (escalation + expansion). The median age was 68 years, 42% were male. Majority were White (63%) and 20% were Black. About 43% had head of pancreas primary tumors and 86% had liver involvement. The median number of lines of prior therapy was 3 (range 1-4). There was no objective response among the 4 patients on DL1; 1 had stable disease (SD) for 11 weeks as best response. 17 of 31 patients on RP2D had only a baseline assessment and came off study for progression of disease, prior to follow-up imaging assessment for response evaluation. Of the 14 RP2D patients with a follow-up assessment, ORR was 0% (3 were SD and 11 had progression of disease (PD) as best response), mPFS - 2.2 mos (95% CI: 1.9, 2.6), mOS - 5.5mos (95% CI: 2.8, 6.5). Treatment related adverse events (TRAEs) of any grade included fatigue (23%), anemia (18%), and increased liver enzymes (9.5%). There were no grade 4-5 TRAEs. Conclusions: The combination Sil/Sparta had an acceptable safety profile but did not elicit responses in advanced PDAC pts. Correlative studies using paired biopsies and blood are ongoing to determine how dual IL-6/PD-1 blockade impacts stromal and immune biomarkers in relationship to the clinical outcome measures. Funding and medications for the study were provided by Novartis and Recordati Rare Diseases Inc (NCT04191421) and NIH/NCI (R21CA266088). Citation Format: Olatunji B. Alese, Olumide Gbolahan, Kathleen M. Coleman, Yichun Cao, Sujata Kane, Sarah Craven, Emily Greene, Natalie Horvat, Andrew McDonald, Walid L. Shaib, Christina S. Wu, Mehmet Akce, Maria Diab, Jeffrey M. Switchenko, Gregory B. Lesinski, Bassel F. El-Rayes. Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT136.",
  "authors": [
    {
      "display_name": "Olatunji B. Alese",
      "id": "A5047220835",
      "orcid": "https://orcid.org/0000-0001-8079-4725",
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Olatunji B. Alese"
    },
    {
      "display_name": "Olumide B. Gbolahan",
      "id": "A5051654669",
      "orcid": null,
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Olumide Gbolahan"
    },
    {
      "display_name": "Kathleen Coleman",
      "id": "A5047171249",
      "orcid": null,
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Kathleen M. Coleman"
    },
    {
      "display_name": "Yichun Cao",
      "id": "A5038794860",
      "orcid": "https://orcid.org/0009-0004-6001-855X",
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Yichun Cao"
    },
    {
      "display_name": "Sujata Kane",
      "id": "A5025954355",
      "orcid": "https://orcid.org/0000-0001-8224-8197",
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Sujata Kane"
    },
    {
      "display_name": "Sarah Craven",
      "id": "A5035396942",
      "orcid": null,
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Sarah Craven"
    },
    {
      "display_name": "Emily R. Greene",
      "id": "A5103266036",
      "orcid": "https://orcid.org/0000-0001-5595-3843",
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Emily Greene"
    },
    {
      "display_name": "Natalie K. Horvat",
      "id": "A5041888697",
      "orcid": "https://orcid.org/0000-0003-2789-8132",
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Natalie Horvat"
    },
    {
      "display_name": "Andrew McDonald",
      "id": "A5114928629",
      "orcid": "https://orcid.org/0000-0002-8824-8224",
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Andrew McDonald"
    },
    {
      "display_name": "Walid L. Shaib",
      "id": "A5064900192",
      "orcid": "https://orcid.org/0000-0001-9388-0446",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Walid L. Shaib"
    },
    {
      "display_name": "Christina Wu",
      "id": "A5029706475",
      "orcid": "https://orcid.org/0000-0001-5922-5392",
      "institutions": [
        {
          "id": "I4210125099",
          "display_name": "Mayo Clinic in Arizona",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Christina S. Wu"
    },
    {
      "display_name": "Mehmet Akce",
      "id": "A5078652492",
      "orcid": "https://orcid.org/0000-0003-4747-7722",
      "institutions": [
        {
          "id": "I32389192",
          "display_name": "University of Alabama at Birmingham",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Mehmet Akce"
    },
    {
      "display_name": "Maria Diab",
      "id": "A5085875893",
      "orcid": "https://orcid.org/0000-0002-4809-9535",
      "institutions": [
        {
          "id": "I154057602",
          "display_name": "Henry Ford Health System",
          "country_code": "US",
          "type": "nonprofit"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Maria Diab"
    },
    {
      "display_name": "Jeffrey M. Switchenko",
      "id": "A5043541884",
      "orcid": "https://orcid.org/0000-0002-5563-9325",
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jeffrey M. Switchenko"
    },
    {
      "display_name": "Gregory B. Lesinski",
      "id": "A5032094154",
      "orcid": "https://orcid.org/0000-0002-8787-7678",
      "institutions": [
        {
          "id": "I150468666",
          "display_name": "Emory University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Gregory B. Lesinski"
    },
    {
      "display_name": "Bassel F. El‐Rayes",
      "id": "A5057176768",
      "orcid": "https://orcid.org/0000-0002-2661-5746",
      "institutions": [
        {
          "id": "I32389192",
          "display_name": "University of Alabama at Birmingham",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Bassel F. El-Rayes"
    }
  ],
  "publication_year": 2024,
  "publication_date": "2024-04-05",
  "type": "article",
  "cited_by_count": 3,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S168522863",
    "display_name": "Cancer Research",
    "issn_l": "0008-5472",
    "issn": [
      "0008-5472",
      "1538-7445"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320273"
  },
  "volume": "84",
  "issue": "7_Supplement",
  "first_page": "CT136",
  "last_page": "CT136",
  "open_access": {
    "is_oa": false,
    "oa_status": "closed",
    "oa_url": null,
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.6615745
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.59941983
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.5186376
    },
    {
      "id": "C2780210213",
      "display_name": "Pancreatic cancer",
      "level": 3,
      "score": 0.5092536
    },
    {
      "id": "C143998085",
      "display_name": "Oncology",
      "level": 1,
      "score": 0.34285533
    }
  ],
  "topics": [
    {
      "id": "T10231",
      "display_name": "Pancreatic and Hepatic Oncology Research",
      "score": 0.9892
    },
    {
      "id": "T10158",
      "display_name": "Cancer Immunotherapy and Biomarkers",
      "score": 0.9765
    },
    {
      "id": "T12505",
      "display_name": "Peptidase Inhibition and Analysis",
      "score": 0.9518
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1158/1538-7445.am2024-ct136",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T15:09:00.130823",
  "source_database": "OpenAlex"
}